Thus, therapeutic targeting of one or more EGFR/ErbB receptors might be useful in correcting diabetes-induced renal vascular dysfunction as well as for reversing the underlying morphological changes and alterations in key renal cell signaling cascades typically associated with DN. This evidence concerns the gene EGFR and liver dysplastic nodule.